Stock JANX JANUX THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Janux Therapeutics, Inc.

Equities

JANX

US47103J1051

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-28 EDT 		5-day change 1st Jan Change
41.89 USD +3.84% Intraday chart for Janux Therapeutics, Inc. +2.27% +290.40%
06-24 Janux Therapeutics, Inc.(NasdaqGM:JANX) added to S&P Biotechnology Select Industry Index CI
06-06 Janux Therapeutics Insider Sold Shares Worth $45,043,975, According to a Recent SEC Filing MT

Evolution of the average Target Price on Janux Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

380c105c43032f78da8857ad.l2WtUzGGVbbKX1ZcVhOmBn8YQ6E_zGfyBQ-wMKIDlgw.5C_8KUftN9moZjJlZV_AT09zC-UHq1fBR1DFU8ty_F_AFPwxRfMRh74bMQ~a59b30d4728e10b4f50fe273e66d8e4f

Analyst Recommendations on Janux Therapeutics, Inc.

Janux Therapeutics Insider Sold Shares Worth $45,043,975, According to a Recent SEC Filing MT
Janux Therapeutics Insider Sold Shares Worth $82,125,000, According to a Recent SEC Filing MT
Scotiabank Starts Janux Therapeutics With Sector Perform Rating MT
Wedbush Raises Janux Therapeutics' PT to $74 From $53, Keeps Outperform Rating MT
JonesTrading Starts Janux Therapeutics With Buy Rating, $70 Price Target MT
BTIG Starts Janux Therapeutics With Buy Rating, $62 Price Target MT
Cantor Fitzgerald Starts Janux Therapeutics With Overweight Rating, $100 Price Target MT
H.C. Wainwright Adjusts Price Target on Janux Therapeutics to $50 From $35, Keeps Buy Rating MT
Wedbush Adjusts Janux Therapeutics' Price Target to $53 From $24; Keeps Outperform Rating MT
Wedbush Starts Janux Therapeutics at Outperform With $24 Price Target, See 'Attractive' Entry Point Ahead of Initial Clinical Data in H2 MT
William Blair Initiates Coverage for Janux Therapeutics With Outperform Rating MT
JANUX THERAPEUTICS : Evercore ISI Starts Janux Therapeutics at Outperform With $35 Price Target MT
JANUX THERAPEUTICS : BofA Securities Starts Janux Therapeutics at Buy With $35 Price Target MT
JANUX THERAPEUTICS : Cowen Initiates Coverage on Janux Therapeutics With Outperform Rating MT
JANUX THERAPEUTICS : HC Wainwright Starts Janux Therapeutics at Buy With $35 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
41.89 USD
Average target price
63.12 USD
Spread / Average Target
+50.69%
High Price Target
100 USD
Spread / Highest target
+138.72%
Low Price Target
25 USD
Spread / Lowest Target
-40.32%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Janux Therapeutics, Inc.

Scotiabank
Wedbush
JonesTrading Institutional Services
BTIG
Cantor Fitzgerald
HC Wainwright
William Blair & Co.
Cowen
Evercore ISI
BofA Securities

Ratings for Janux Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. JANX Stock
  4. Consensus Janux Therapeutics, Inc.